917
Insulin Resistance and Progression to Liver Fibrosis in HIV/HCV-co-infected Patients Participating to the Prospective ANRS Co13 French Cohort Study
Dominique Salmon*1, M A Loko2, S Dominguez3, P Bonnard4, P Morlat5, L Merchadou2, P Sogni1, L Alric6, F Dabis2, and Y Benhamou3
1Hosp Cochin, Paris, France; 2INSERM U593, Univ Victor Segalen, Bordeaux, France; 3Hosp Pitie Salpetriere, Paris, France; 4Hosp Tenon, Paris, France; 5Hosp St-Andre, Bordeaux, France; and 6Hosp Purpan, Toulouse, France
Background: Insulin resistance has been reported in
patients with chronic hepatitis C virus (HCV). In HCV-mono-infected patients,
insulin resistance has been associated with more rapid progression of liver
fibrosis. However, the effect of insulin resistance on liver fibrosis in
HIV/HCV co-infected is unknown. Our objective was to analyze the effect of insulin
resistance as determined by HOMA score on liver fibrosis in HIV/HCV-co-infected
patients.
Methods: HIV/HCV-co-infected patients, enrolled in a prospective
French cohort study with available baseline blood measurements for fasted
glycemia and insulinemia, and evaluation of fibrosis by either FibroTest or
FibroScan were included in the current analysis. Univariate analysis was used
to measure association between insulin resistance and severe liver fibrosis
evaluated by FibroTest and FibroScan. (F≥3, METAVIR). Thresholds used for the diagnosis
of severe liver fibrosis are those reported in publications ie, FibroScan >9.5,
FibroTest >0.68. For
an accurate measurement of FibroTest that includes total serum bilirubin,
patients receiving atazanavir were excluded. Insulin resistance was defined by
a HOMA score (glycemia x insulinemia)/ 22.5) >4.
Results: We included 130 HIV/HCV-co-infected patients,
whose mean was age 44 (range 31 to 70) years, and of whom 76.9% were male. HOMA
score >4 was found in 26.9% of the patients. Patients with insulin
resistance had a higher body mass index (p
= 0.0002), higher aspartate aminotransferase (AST) (p = 0.004), higher alanine aminotransferase (ALT) (p = 0.02), higher g-glutamyl
transferase (p = 0.003) than patients without insulin
resistance. HCV genotype repartition did not differ between the 2 groups. When
using FibroScan, the risk of severe liver fibrosis was significantly increased
in patients with insulin resistance as compared to patients without insulin
resistance (OR 4.2, 95%CI 1.4 to 12.7, p
= 0.01). When using FibroTest, the same tendency was found but the relationship
did not reach the significant level (OR 2.5, 95%CI 0.5 to 12, p = 0.28).
Conclusions: A high prevalence of insulin resistance was
found in the studied population. This study suggests that insulin resistance may
be associated with more severe liver fibrosis in HIV/HCV-co-infected patients.
Further studies that include liver biopsies are needed to assess the role
of insulin resistance on liver lesions and its effect on anti-HCV therapy.
|